Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Nov 01, 2005 (Vol. 25, No. 19)

ZINC is not Commercial

URL:blaster.docking.org/zinc
  • Number of chemicals
  • Lack of clarity
Another one of those sites about which I say "hmmmm." ZINC is not Commercial is a site that Shakespeare might have advised, "Though doth protest too much." I guess being commercial is a risk when housing a database of commercially available compounds. As stated at the site, "ZINC contains over 3.3 million compounds in ready-to-dock, 3-D formats." Ready to dock? Binding of a ligand to a protein receptor, dummy. Another comment was more puzzling—ZINC provides "a free database of commercially available compounds for virtual screening." Virtual screening? I couldn't figure that one out. There appears to be a lot offered here, but the lack of descriptions and poor organization will leave most visitors wanting more. I certainly did.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »